Deformable Image Registration for Breast Adaptive Tomotherapy (DIRB-ATOM)
Quantitative Evaluation of the Performance of a Deformable Registration Algorithm: Single-center Study Aimed at Implementing a New Off-line Adaptive Radiotherapy Technique in the Treatment of Breast Cancer by Tomotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Strasbourg, France, 67033
- Institut de cancérologie Strasbourg Europe
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Female
- With invasive breast carcinoma (or axillary lymphadenopathy whose pathological examination is compatible with the origin of breast cancer but without an identified primary breast tumor)
- Breast surgery (conservative surgery or mastectomy)
- Treated by (neo)adjuvant chemotherapy or hormonotherapy
- eligible to normo-fractionated breast radiotherapy in 25 sessions of 2 Gray or 15 sessions of 2.67 Gray, associated or not to bed irradiation whatever the delivered dose
- eligible to an irradiation of sus-clavicular, inner mammary chain or axillary lymph nodes
- With helicoidal tomotherapy
Exclusion Criteria:
- Absence of indication for breast radiotherapy
- Absence of indication for lymph nodes irradiation
- partial irradiation of breast
- in situ carcinoma
- intranodal isolated tumor cells
- radiotherapy on prosthesis or surgically reconstructed breast
- antecedent of breast irradiation opr homolateral lymh node irradiation
- bilateral breast cancer
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences between dosimetric metrics on deformed and delineated contours.
Time Frame: Before treatment
|
Description of the differences between metrics calculated on delineated contours and contours deformed by artificial intelligence
|
Before treatment
|
|
Differences between dosimetric metrics on deformed and delineated contours.
Time Frame: Mid-treatment : after fraction 7 for patients with 15 fractions (theoretically at day 9) or after fraction 12 for patients with 25 fractions (theoretically at day 16)
|
Description of the differences between metrics calculated on delineated contours and contours deformed by artificial intelligence
|
Mid-treatment : after fraction 7 for patients with 15 fractions (theoretically at day 9) or after fraction 12 for patients with 25 fractions (theoretically at day 16)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.